A 48-year-old woman with poorly controlled type 2 diabetes (HbA1c 10.2%) undergoes routine dilated fundoscopy. She is found to have multiple microaneurysms, dot-blot hemorrhages, and hard exudates in the four quadrants, but no cotton-wool spots, intraretinal microvascular abnormalities, or neovascularization. She is asymptomatic with visual acuity 6/6 in both eyes. Which investigation is most appropriate to determine if she requires immediate laser photocoagulation?

Explanation

## Investigation to Guide Photocoagulation in Moderate NPDR ### Clinical Context The patient has **moderate nonproliferative diabetic retinopathy (NPDR)** — defined by: - Multiple microaneurysms and hemorrhages in all four quadrants - Hard exudates (lipid deposits) - **Absence of** cotton-wool spots, IRMA, or neovascularization The critical question is: **Does she have clinically significant macular edema (CSME) requiring laser, or ischemic retina at risk of progression to PDR?** ### Why FFA is Essential Here **Key Point:** FFA is the gold standard for determining photocoagulation candidacy because it: 1. **Detects CSME** — defined by FFA leakage within 500 µm of the fovea center, or hard exudates within 500 µm with thickening on OCT 2. **Maps areas of capillary nonperfusion (ischemia)** — indicates risk of progression to PDR 3. **Guides focal photocoagulation** — laser burns placed directly on leaking microaneurysms 4. **Identifies panretinal photocoagulation (PRP) indications** — if extensive ischemia detected **High-Yield:** The Early Treatment Diabetic Retinopathy Study (ETDRS) established that FFA-defined CSME is the criterion for initiating photocoagulation. Clinical findings alone (hard exudates, edema on fundoscopy) are insufficient — FFA leakage must be documented. **Clinical Pearl:** This patient is asymptomatic with 6/6 vision, so she may not have macular involvement. However, FFA is still mandatory to: - Confirm absence of CSME (if absent, observe and optimize glycemic control) - Detect ischemic zones (if extensive, consider PRP to prevent PDR progression) - Establish baseline for future monitoring ### Comparison of Investigations | Investigation | Detects CSME? | Detects Ischemia? | Guides Laser? | Role in This Case | |---|---|---|---|---| | **FFA** | ✓ (gold standard) | ✓ (capillary nonperfusion) | ✓ (maps leakage) | **Essential — determines treatment** | | **OCT (macular)** | ✓ (edema thickness) | ✗ (structural only) | ✗ (shows anatomy, not leakage) | Complementary; confirms edema if FFA shows leakage | | **Goldmann perimetry** | ✗ | ✗ | ✗ | Detects optic nerve/visual field; not for DR staging | | **ICGA** | ✗ | ✗ | ✗ | Assesses choroid; not used in DR management | ### Decision Algorithm ```mermaid flowchart TD A[Moderate NPDR on fundoscopy]:::outcome --> B{FFA findings?}:::decision B -->|CSME present| C[Focal photocoagulation]:::action B -->|Extensive ischemia| D[Panretinal photocoagulation]:::action B -->|No CSME, no extensive ischemia| E[Observe + optimize glycemic control]:::action C --> F[Repeat FFA in 3-4 months]:::action D --> G[Repeat FFA in 1 month]:::action E --> H[Repeat FFA annually]:::action ``` **Mnemonic: "FFA Before Laser"** - **F**undus examination → identifies DR - **F**luorescein angiography → confirms CSME & ischemia - **A**ction → photocoagulation if indicated [cite:ETDRS Report No. 1; Harrison 21e Ch 424]